Shift of Domestic Clinical Trials Overseas
First written in FY2016. 4 of 5 entries say "Restated". Latest entry: FY2024.
2 other companies' latest entry also says "Restated".
- FY2024RestatedAnnual report
「If the globalisation and overseas shift of the clinical trial environment occur at a pace far exceeding the Group's assumptions, causing the scale and number of clinical trials conducted in Japan to decline rapidly, the Group's performance could be affected.」
The risk of a contraction in the domestic market due to the shift of domestic clinical trials overseas continues to be disclosed, along with responses through the Group's own sites and partnerships in the United States, Europe and Asia. - FY2020RestatedAnnual report
「However, Japan continues to account for a large share of the Group's regional sales. If the clinical trial environment globalises at a pace far exceeding the development and progress of the Group's global pharmaceutical development infrastructure, and the use of overseas clinical trial data in domestic applications accelerates sharply, reducing the number of clinical trials conducted in Japan and the number of clinical trials contracted by the Group, the Group's performance could be affected.」
Given that Japan continues to account for a large share of sales, the risk of a decline in domestic clinical trials and contracted trials as the use of overseas clinical trial data in Japan accelerates is reiterated. - FY2018RestatedAnnual report
「However, Japan continues to account for a large share of the Group's regional sales. If the clinical trial environment globalises at a pace far exceeding the development and progress of the Group's global pharmaceutical development infrastructure, and the use of overseas clinical trial data in domestic applications accelerates sharply, reducing the number of clinical trials conducted in Japan and the number of clinical trials contracted by the Group, the Group's performance could be affected.」
Given that Japan continues to account for a large share of sales, the risk of a decline in domestic clinical trials and contracted trials as the use of overseas clinical trial data in Japan accelerates continues to be disclosed. - FY2017RestatedAnnual report
「However, if the plan remains ineffective and the use of overseas clinical trial data in domestic applications accelerates in accordance with the guidelines, the number of clinical trials conducted in Japan could decline, affecting the Group's performance through a decrease in the number of clinical trials contracted.」
The risk of a decline in the number of domestic clinical trials and contracted trials if the use of overseas clinical trial data in domestic applications accelerates is reiterated. - FY2016First statedAnnual report
「However, if the plan remains ineffective and the use of overseas clinical trial data in domestic applications accelerates in accordance with the guidelines, the number of clinical trials conducted in Japan could decline, affecting the Group's performance through a decrease in the number of clinical trials contracted.」
The disclosure indicates that increased use of overseas clinical trial data in domestic applications could reduce the number of clinical trials conducted in Japan and the number of contracted trials.